Memantine Hydrochloride Solution
Product Images NDC 62135-943

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 62135-943). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Memantine Hydro Bot Label)

Label for Memantine Hydrochloride Oral Solution 2 mg/mL, a prescription drug in a 240 mL (8 fl oz) bottle. The label indicates Rx only and provides storage instructions. It is manufactured by Chartwell Pharmaceuticals, distributed by Chartwell RX, and includes a barcode and NDC 62135-943-37. The label also references patient information availability online.*

FDA Label Image

Image Description (Memantine Hydro Fig 1)

A line graph showing mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine and Placebo groups. The Y-axis represents mean change with clinical improvement and decline indicated, while the X-axis shows weeks of treatment at 0, 4, 12, and 28 weeks. Memantine shows less decline over time compared to placebo.*

FDA Label Image

Image Description (Memantine Hydro Fig 2)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline. The graph compares effects between Memantine and placebo groups, with the x-axis representing the ADCS-ADL change scores and the y-axis showing the cumulative percentage of patients. Memantine is indicated by circles and placebo by squares.*

FDA Label Image

Image Description (Memantine Hydro Fig 3)

A line graph showing mean (± SEM) change from baseline in Severe Behavioral Index (SBI) score over 28 weeks of treatment. The graph compares placebo and Memantine groups, indicating clinical improvement or decline based on score changes. Memantine group shows stabilization or slight improvement, while placebo shows worsening over time.*

FDA Label Image

Image Description (Memantine Hydro Fig 4)

A line graph showing the cumulative percentage of patients versus SIB change from baseline. Two lines are plotted: one for placebo (solid squares) and one for Memantine (open circles). The Memantine group shows a higher cumulative percentage of patients with greater negative SIB change compared to placebo.*

FDA Label Image

Image Description (Memantine Hydro Fig 5)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment for two groups: Placebo/Donepezil (solid squares) and Memantine/Donepezil (open circles). The y-axis shows mean change (± SEM) with clinical improvement and decline markers; the x-axis shows weeks of treatment. Error bars represent variability.*

FDA Label Image

Image Description (Memantine Hydro Fig 6)

Kaplan-Meier curve showing cumulative percentage of patients versus ADCS-ADL change from baseline, comparing Placebo/Donepezil (black squares) and Memantine/Donepezil (open circles) treatment groups. The horizontal axis displays ADCS-ADL change from baseline, and the vertical axis shows cumulative percentage of patients, illustrating functional change over time.*

FDA Label Image

Image Description (Memantine Hydro Fig 7)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment. It compares two groups: Placebo/Donepezil and Memantine/Donepezil. The y-axis measures mean change ± SEM, with clinical improvement above zero and clinical decline below. The Memantine/Donepezil group shows increasing improvement peaking around week 12, while Placebo/Donepezil shows little change and eventual decline.*

FDA Label Image

Image Description (Memantine Hydro Fig 8)

A cumulative percentage graph showing patients' SIB (Severe Impairment Battery) score changes from baseline. The graph compares Placebo/Donepezil treatment (squares) and Memantine/Donepezil treatment (circles), illustrating cumulative patient response percentages along a range of negative SIB score changes.*

FDA Label Image

Image Description (Memantine Hydro Pi Fig 1)

An instructional illustration showing a person administering an oral liquid solution using a dropper. One hand holds the dropper, squeezing it to release the liquid onto the other hand's palm or fingers. This image is relevant for dosing liquid oral medications like Memantine Hydrochloride solution.*

FDA Label Image

Image Description (Memantine Hydro Pi Fig 2)

An instructional line drawing showing a hand holding a bottle and another hand using a dropper or syringe to withdraw liquid from the bottle. The illustration demonstrates the proper technique for drawing liquid medication from a bottle using a dropper or syringe.*

FDA Label Image

Image Description (Memantine Hydro Pi Fig 3)

An instructional illustration showing a hand holding a small bottle while drawing liquid into a syringe, with an arrow indicating the upward direction of the liquid inside the syringe. This likely demonstrates how to measure or withdraw an oral solution dose accurately.*

FDA Label Image

Image Description (Memantine Hydro Structure)

Chemical structure of Memantine Hydrochloride, showing a bicyclo[2.2.1]heptane skeleton with amino and methyl substituents and associated hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.